Perioperative Beta-Blocker Management
CA-2 · II.C.1.c.2.a.4 II.D.3.i.6 II.D.2.g.6.b
24Sources
6Kept
0Dropped
6 points
Pooling only the trials whose data remain secure, starting a beta-blocker before noncardiac surgery increased 30-day all-cause mortality by 27%, and increased stroke and hypotension while reducing non-fatal myocardial infarction.
PMID 23904357
kept
Starting extended-release metoprolol before noncardiac surgery reduced myocardial infarction from 5.7% to 4.2% but increased death from 2.3% to 3.1% and doubled stroke from 0.5% to 1.0%.
PMID 18479744
kept
The association between perioperative beta-blockade and survival tracks baseline risk: benefit appeared at a Revised Cardiac Risk Index of 2 or more, with no benefit and possible harm at a score of 0 or 1.
PMID 16049209
kept
Ultra-short-acting agents such as esmolol and landiolol offer the effects of beta-blockade without the detrimental effects of long-acting agents, which are hard to counteract once given perioperatively.
PMID 29398384
kept
Beta-blocker exposure around major noncardiac surgery was associated with lower 30-day mortality only in patients with two or more Revised Cardiac Risk Index factors, and only in nonvascular surgery.
PMID 23613075
kept
Long-term preoperative beta-blocker prescription is independently associated with increased postoperative ischaemic stroke risk at 30 and 365 days, especially in lower-risk patients.
PMID 42290631
kept
Decks
Oral boards prompts for you
No module in the boards bank matches this topic yet.